Substantive Updates Part Two: What Women Leaders in Life Sciences Law Must Know About Crucial Intellectual Property Protection and Enforcement Strategies

July 28, 2016 1:30pm

Zoya Marriott
Cornerstone Research

Delphine W. Knight Brown
Axinn, Veltrop & Harkrider LLP (New York, NY)

Kathleen Gersh
Senior Counsel
Loeb & Loeb LLP (New York, NY)

Jennifer L. Fox
Brinks Gilson Lione

Elizabeth A. McGraw
General Patent Counsel, Elanco Animal Health Sr Dir., Assistant General Patent Counsel
Eli Lilly and Company (Greenfield, IN)

  • Overview and updates on key life sciences cases pending before the Supreme Court and Federal Circuit
  • Anticipating how the pending implementation of the Defense of Trade Secrets Act will affect life sciences patent strategies
  • Exploring the uncertainty in the new patent landscape for biopharma and medical device companies: concerns over what is patentable after Myriad and Sequenom; patent portfolios hanging in the balance post-Gilead; and quasilitigation at the USPTO
  • Understanding antitrust implications for settlements post-Actavis
  • Preparing for the challenges as biosimilars, 3D printing, and personalized medicine become realities